MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00259-025-07518-2

Медицинская библиотека · European journal of nuclear medicine and molecular imaging · 2025

[18F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.

Breukers Sabine E, Crommelin Robert D, Smit Laura A, de Boer Jan Paul, Navran Arash, van Houdt Winan J, de Bree Remco, Devriese Lot A, Haanen John B A G, Wondergem Maurits, Zuur Charlotte L, Vogel Wouter V

СтатьяРандомизированное исследованиеКлиническое исследование II фазыПеревод пока не подготовлен

Аннотация

PURPOSE: Ultra-short immunotherapy may spare cutaneous squamous cell carcinoma (CSCC) patients from mutilating surgery, but early identification of (non-)response is needed to safely guide treatment adaptation. This study evaluated the feasibility of sequential [18F]FDG-PET/CT (FDG-PET) as a response biomarker in resectable CSCC patients.

METHODS

In the MATISSE, a randomized phase-II trial, 50 CSCC patients received two courses of neoadjuvant nivolumab (weeks 0 and 2) with or without low-dose ipilimumab (week 0) before surgery (week 4). FDG-PET scans were obtained pre-treatment and shortly prior to surgery to assess the change (Δ) in maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) at the primary tumour and largest (= index) lymph node metastasis (ILN). ΔMTV50%/4.0 and ΔTLG50%/4.0 were calculated using thresholds of 50% SUVmax and SUV ≥ 4.0.

RESULTS

In 42 evaluable patients, 31 (74%) patients showed major or partial responses to immunotherapy. EORTC-criteria underestimated response but accurately identified non-responders (70% sensitivity, 100% specificity). In 28 primary tumours and 22 ILNs, a significant reduction in median SUVmax, MTV50%, MTV4.0, TLG50%, and TLG4.0 was observed in responders versus non-responders (overall, p ≤ 0.004, and p ≤ 0.03, respectively). ΔTLG50% and ΔTLG4.0 correlated strongly with response (primary: 92% and 96% accuracy; ILN: 91% and 89% accuracy).

CONCLUSIONS

Quantitative FDG-PET-response assessment allows early identification of (non-)responders upon neoadjuvant immunotherapy prior to surgery in locoregionally advanced CSCC patients. Early changes in FDG-PET's TLG can support future trials aiming at safe de-escalation of current standard of care surgery with or without adjuvant radiotherapy.

TRIAL REGISTRATION: EudraCT 2020-001074-30. Registered 9 March 2020, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001074-30.

Для цитирования: Breukers Sabine E, Crommelin Robert D, Smit Laura A, de Boer Jan Paul, Navran Arash, van Houdt Winan J, de Bree Remco, Devriese Lot A, Haanen John B A G, Wondergem Maurits, Zuur Charlotte L, Vogel Wouter V. [18F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.. European journal of nuclear medicine and molecular imaging. 2025. DOI: 10.1007/s00259-025-07518-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.